About MannKind

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer.

In addition, MannKind is applying our novel technologies and services to support partner development efforts. More >

Our lead investigational product candidate, AFREZZA®
(pronounced uh-FREZZ-uh)
is a novel, ultra rapid-acting mealtime insulin therapy being studied for the treatment of adult patients with Type 1 and Type 2 diabetes mellitus for the control of hyperglycemia. More >

 

Spotlight

MannKind has completed recruiting patients for the Affinity1 (Type 1) and Affinity2 (Type 2) clinical studies.

Read the press release here.

News & Events

   
May 09, 2013 MannKind Corporation Reports 2013 First Quarter Financial Results More >
May 08, 2013 MannKind to Present at Bank of America Merrill Lynch 2013 Health Care Conference More >
May 02, 2013 MannKind Corporation to Hold 2013 First Quarter Financial Results Conference Call... More >